Takeda Expected to Post Second-Quarter Net Profit -- Earnings Preview

Dow Jones10-30

By Kosaku Narioka

Takeda Pharmaceutical is scheduled to report its second-quarter results on Thursday. Here is what you need to know:

NET PROFIT: Takeda is expected to post net profit of 50.0 billion yen, equivalent to $326.0 million, for the three months ended Sept. 30, according to a poll of analysts by Visible Alpha. That would compare with net loss of Y48.0 billion in the year-earlier period.

REVENUE: Second-quarter revenue is estimated to have increased 5.7% to Y1.103 trillion, according to the Visible Alpha poll.

The company's shares have risen nearly 5% year to date, closing at Y4,251 on Wednesday.

WHAT TO WATCH:

--The first-quarter's revenue increase was driven by sales growth of several key products. Sales of ulcerative colitis drug Entyvio rose 22% to Y234.4 billion and sales of plasma-derived products gained 30% to Y271.4 billion. Investors will be focusing on the pace of sales growth for these key products.

--For the fiscal year ending March 2025, Takeda has projected revenue to increase 2.0% to Y4.350 trillion but net profit to fall 60% to Y58.00 billion. Investors will be closely watching any changes to the annual guidance management may make.

--The company's operating profit margin deteriorated to 13.8% in its first quarter from 15.9% a year earlier. Investors will be paying attention to margin trends as businesses globally are dealing with relatively high inflation.

Write to Kosaku Narioka at kosaku.narioka@wsj.com

(END) Dow Jones Newswires

October 30, 2024 06:55 ET (10:55 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2479119277?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-30 18:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2479119277","market":"hk","top_or_hot":-1,"title":"Takeda Expected to Post Second-Quarter Net Profit -- Earnings Preview","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Kosaku Narioka \n</p>\n<pre>\n \n</pre>\n<p>\n  Takeda Pharmaceutical is scheduled to report its second-quarter results on Thursday. Here is what you need to know: \n</p>\n<pre>\n \n</pre>\n<p>\n  NET PROFIT: Takeda is expected to post net profit of 50.0 billion yen, equivalent to $326.0 million, for the three months ended Sept. 30, according to a poll of analysts by Visible Alpha. That would compare with net loss of Y48.0 billion in the year-earlier period. \n</p>\n<p>\n  REVENUE: Second-quarter revenue is estimated to have increased 5.7% to Y1.103 trillion, according to the Visible Alpha poll. \n</p>\n<p>\n  The company's shares have risen nearly 5% year to date, closing at Y4,251 on Wednesday. \n</p>\n<pre>\n \n</pre>\n<p>\n  WHAT TO WATCH: \n</p>\n<p>\n  --The first-quarter's revenue increase was driven by sales growth of several key products. Sales of ulcerative colitis drug Entyvio rose 22% to Y234.4 billion and sales of plasma-derived products gained 30% to Y271.4 billion. Investors will be focusing on the pace of sales growth for these key products. \n</p>\n<p>\n  --For the fiscal year ending March 2025, Takeda has projected revenue to increase 2.0% to Y4.350 trillion but net profit to fall 60% to Y58.00 billion. Investors will be closely watching any changes to the annual guidance management may make. \n</p>\n<p>\n  --The company's operating profit margin deteriorated to 13.8% in its first quarter from 15.9% a year earlier. Investors will be paying attention to margin trends as businesses globally are dealing with relatively high inflation. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Kosaku Narioka at kosaku.narioka@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 30, 2024 06:55 ET (10:55 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Takeda Expected to Post Second-Quarter Net Profit -- Earnings Preview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTakeda Expected to Post Second-Quarter Net Profit -- Earnings Preview\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-30 18:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Kosaku Narioka \n\n\n \n\n\n  Takeda Pharmaceutical is scheduled to report its second-quarter results on Thursday. Here is what you need to know: \n\n\n \n\n\n  NET PROFIT: Takeda is expected to post net ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TAK","symbol_name":"武田制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2479119277","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479119277","pubTimestamp":1730285700,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Takeda Pharmaceutical is scheduled to report its second-quarter results on Thursday. Here is what you need to know:. NET PROFIT: Takeda is expected to post net profit of 50.0 billion yen, equivalent to $326.0 million, for the three months ended Sept. 30, according to a poll of analysts by Visible Alpha. That would compare with net loss of Y48.0 billion in the year-earlier period.REVENUE: Second-quarter revenue is estimated to have increased 5.7% to Y1.103 trillion, according to the Visible Alpha poll.The company's shares have risen nearly 5% year to date, closing at Y4,251 on Wednesday.--The first-quarter's revenue increase was driven by sales growth of several key products. Sales of ulcerative colitis drug Entyvio rose 22% to Y234.4 billion and sales of plasma-derived products gained 30% to Y271.4 billion. Investors will be focusing on the pace of sales growth for these key products.--For the fiscal year ending March 2025, Takeda has projected revenue to increase 2.0% to Y4.350 trilli","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"TAK":"武田制药","POST":"Post Holdings"},"translate_title":"武田预计公布第二季度净利润——盈利预览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"POST":1,"TAK":0.9},"content_text":"By Kosaku Narioka \n\n\n \n\n\n  Takeda Pharmaceutical is scheduled to report its second-quarter results on Thursday. Here is what you need to know: \n\n\n \n\n\n  NET PROFIT: Takeda is expected to post net profit of 50.0 billion yen, equivalent to $326.0 million, for the three months ended Sept. 30, according to a poll of analysts by Visible Alpha. That would compare with net loss of Y48.0 billion in the year-earlier period. \n\n\n  REVENUE: Second-quarter revenue is estimated to have increased 5.7% to Y1.103 trillion, according to the Visible Alpha poll. \n\n\n  The company's shares have risen nearly 5% year to date, closing at Y4,251 on Wednesday. \n\n\n \n\n\n  WHAT TO WATCH: \n\n\n  --The first-quarter's revenue increase was driven by sales growth of several key products. Sales of ulcerative colitis drug Entyvio rose 22% to Y234.4 billion and sales of plasma-derived products gained 30% to Y271.4 billion. Investors will be focusing on the pace of sales growth for these key products. \n\n\n  --For the fiscal year ending March 2025, Takeda has projected revenue to increase 2.0% to Y4.350 trillion but net profit to fall 60% to Y58.00 billion. Investors will be closely watching any changes to the annual guidance management may make. \n\n\n  --The company's operating profit margin deteriorated to 13.8% in its first quarter from 15.9% a year earlier. Investors will be paying attention to margin trends as businesses globally are dealing with relatively high inflation. \n\n\n \n\n\n  Write to Kosaku Narioka at kosaku.narioka@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 30, 2024 06:55 ET (10:55 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2479119277"}